Physical fitness has a significant impact on renal function and chronic kidney disease in diabetes, according to a new study that provides hope for preventing or delaying the need for dialysis.
You have reduced this patient's A1C to 6.9% by adding insulin. Suboptimal lipids and persistent hypertension now must be addressed. What change(s) would you make to her regimen?
Half of patients with pancreatic cancer have DM at diagnosis; long-standing type 1 or type 2 DM may increase the risk of pancreatic cancer by 40% to 100%. Which comes first? Consider the studies, here.
Chronic kidney disease is common in patients with diabetes and can complicate treatment, but several agents may help. Here the focus is on incretin therapies.
How does "pattern care" differ from "step therapy"? Does the bionic pancreas work? Why is incretin therapy taking off? Here, a 5-slide review of these and other hot topics from the 2014 ADA Scientific Sessions.
Progressive β-cell failure is a core defect of type 2 diabetes; most patients will eventually need insulin replacement therapy. When is the right time? Here, 5 scenarios that may help you make a decision.
Posters at ADA 2014 showcased growing popularity of the incretin therapies and SGLT2 inhibitors. Most fascinating to this diabetologist blogger was use of insulin and a GLP-1 RA in a fixed-combination product.
The latest version of this wearable, automated device can improve glycemia without increasing hypoglycemia. It can handle a wide range of dosing requirements.
Insulin resistance in obese persons at risk for diabetes may be improved with resveratrol used as a dietary supplement, but don’t expect health benefits from resveratrol in red wine.
A genetic variant involved in regulating food intake may play a role in how body mass index affects patients’ susceptibility to diabetes. Reducing total energy intake might help prevent obesity.
The endocrinologist, the primary care physician, the nurse practitioner: who will do what in the coming days of diabetes care? Just one of the debates going on at the ADA conference.
Here's why incretins are catching on . . . and a strategy that treats not just the whole patient but the whole problem. Live from the ADA convention, highlights here.
Correcting Vitamin D deficiency in susceptible diabetes patients could have considerable metabolic benefit.
An A1C goal less stringent than 7% may be appropriate for some patients. In what patients might you make the goal 8%?
For which patients might a less stringent A1C goal -- of 8% -- be appropriate? A quiz, and the answer here.